Objective
This study developed a multiomics model combining radiomics, pathomics, and temporal imaging to predict major pathological response in patients with locally advanced non-small cell lung cancer (NSCLC) undergoing neoadjuvant immunochemotherap…
Background
Challenges in predicting which neoantigens mediate tumor rejection limit the efficacy of neoantigen vaccines to treat cancers, especially for cancers with a high mutational burden like cutaneous squamous cell carcinoma (cSCC). Only a small …
Targeted resistance to immune checkpoint therapy remains a clinical challenge, and a recent study reported by Xie et al provides novel insights into how RNA acetylation, particularly N4-acetylcytidine (ac4C), plays a pivotal role in shaping the tumor …
Background
Patients with colon cancer liver metastases (CCLM) frequently exhibit poor responses to immunotherapy, a phenomenon attributed in part to an immune desert tumor microenvironment. This study aimed to comprehensively characterize the immune l…
Immune checkpoint inhibition (ICI) has become a first-line treatment strategy for advanced hepatocellular carcinoma (HCC). However, treatment efficacy remains varied, and there are no reliable biomarkers of response. We used phage immunoprecipitation …
Imiquimod is a standard therapy option for vulvar high-grade squamous intraepithelial lesions (vHSIL). In a retrospective study, the pre-existing composition of the immune cell infiltrate was associated with clinical outcome after imiquimod treatment….
Background
Malignant perivascular epithelioid cell tumors (PEComas) are ultra-rare, aggressive mesenchymal neoplasms associated with poor outcomes. Standard-of-care systemic therapy includes mammalian target of rapamycin (mTOR) inhibition and chemothe…
Background
The immunosuppressive tumor microenvironment reduces immune response effectiveness in stromal-rich tumors, including consensus molecular subtype 4 colorectal cancer (CRC). Mesenchymal stromal cells (MSCs), precursors to cancer-associated fi…
Background
Beyond supporting cancer cell proliferation, tumor growth relies on the ability of cancer cells to evade immune surveillance. Identifying novel molecules that promote tumor immune escape may help develop more effective immunotherapeutic str…
Background
Triple-negative breast cancer (TNBC) is a highly aggressive subtype of breast cancer that lacks hormone receptors and human epidermal growth factor receptor 2 (HER2) amplification, making it unresponsive to standard hormone or HER2-targeted…
